Clinical decision-support only. For use by licensed dental professionals. Not a substitute for professional judgment or a complete drug reference. Always verify with primary sources.
← Back to search
Medication

Ampicillin

Antibiotic (aminopenicillin)

Brand names: Principen

Oral health effects

  • Oral candidiasis (thrush)

    Broad-spectrum antibiotics suppress commensal bacteria, allowing Candida overgrowth in the mouth.

    Mechanism: Loss of competitive inhibition from normal flora.

    Clinical management: Watch for thrush, especially with repeated courses; treat with an antifungal; reinforce hygiene.

  • Antibiotic-associated diarrhea / gut dysbiosis

    Disruption of gut flora can cause diarrhea and C. difficile overgrowth.

    Clinical management: A probiotic (e.g., Saccharomyces boulardii) during the course may modestly lower the risk of antibiotic-associated diarrhea; the evidence is low certainty. Avoid probiotics in immunocompromised or severely ill patients. See the Gut Health page.

  • Sore mouth or tongue (glossitis, stomatitis)

    Glossitis and stomatitis are listed adverse reactions and are usually linked to oral dosage forms. Some patients report a sore mouth or tongue. Frequency not stated.

    Clinical management: Bland rinses (saline or sodium bicarbonate) and a soft toothbrush. Avoid irritating products. Check for candidiasis. Refer to the prescriber if lesions are severe or come with a rash, because ampicillin rash can involve the oral mucosa.

Sources

  1. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. Hempel S, Newberry SJ, Maher AR, et al. JAMA, 2012.
  2. Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children. Esmaeilinezhad Z, Ghosh NR, Walsh CM, et al. The Cochrane database of systematic reviews, 2025.
  3. Common Oral Conditions: A Review. Stoopler ET, Villa A, Bindakhil M, et al. JAMA, 2024.
  4. Ampicillin prescribing information (FDA label) REMEDYREPACK INC. / DailyMed, 2026.